Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intervention of Henagliflozin on Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes Mellitus (T2DM)

NCT06762223 is registered in ClinicalTrials.gov with Xiqiao Zhou as lead sponsor.

NCT NCT06762223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06762223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intervention of Henagliflozin on Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes Mellitus (T2DM)
Lead sponsor
Xiqiao Zhou
Phase
Phase 4
Overall status
Not yet recruiting
Start date
December 31, 2024
Completion date
December 31, 2026
Enrollment
190 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus